Sterinnova
Ventures
Venture Studio & Venture Capital Fund
Building and investing in the next generation of infection risk control companies.
Cambridge, MA · Kendall Square
The Problem
Infection Risk Control: a critical sector, ready for innovation.
Strategic Players Without Innovation Arms
The largest incumbents in sterilization lack dedicated vehicles to source, build, and scale breakthrough technology.
No Innovation in 30 Years
Core infection risk control methods have remained virtually unchanged for three decades while adjacent industries leapt forward.
Limited Access to Capital and Sandboxes
Founders face scattered funding sources and limited regulatory sandboxes to validate new approaches.
Still a Public-Health Risk
Healthcare-associated infections remain a persistent, costly, and deadly global public-health challenge. More than 10% of surgeries worldwide are canceled due to infection control problems.
Sterinnova bridges the gap.
Why Sterinnova
Where founders, capital, and operators converge.
Sterinnova is investing and building the next generation of companies in the space, bringing together founders, ideas, capital, access, and a pool of sandboxes worldwide.
What we do best
Smart Capital & Network
Capital with value-add, beyond funding. Access to strategic players and cutting-edge university researchers, with a team of GPs and advisors with deep sector knowledge.
Worldwide Access to Sandboxes
Sandbox companies to test and scale across the US, LATAM, EU and MEA.
Research & IP Repurposing
Proprietary model to repurpose existing IP and university research into real solutions for infection risk control, ready to commercialize.
Sector Expertise
40+ yrs of track record in Healthcare & Infection Risk Control. Operator, investor & founder mindset.
Engagement Models
Two ways we partner with founders.
Two business models that support and invest in market-defining companies.
We build companies from the ground up.
We originate ideas inside the sterilization value chain, validate them against real clinical and regulatory needs, and spin up new companies, from ProtoCo to NewCo, with our team embedded as co-founders from day one.
Full-stack support, in-house
We invest in and scale what already exists.
We back exceptional startups and companies already operating in infection risk control, then help them scale, integrate, or exit, pairing capital with the operating muscle and strategic network the sector has lacked.
What we bring
- → Strategic capital, and access to strategic players
- → Sandboxes, and university research
- → Operating support from founders, investors, and operators
- → A clear path to scale and integrate
Support
We move when others can't. Large strategics lack the agility to sandbox new technologies, so we provide the speed and focus they can't build in-house.
Experience
We've been on both sides of the table. As founders, investors, and operators in infection risk control, we've lived the full journey from IP to exit.
Community
We're the network this sector was missing. No specialized venture builder has existed to source, build, and channel infection risk control innovation to strategic players. Until now.
Investment Thesis
From idea to exit.
Every company starts as a question. We source signals, stress-test them, build the winners, and scale them out, turning "What if…" into "It works."
Phase 1
Exploration
Hypothesis Generation
- · Market white space mapped by sector hypotheses and existing IP
- · Network engaged to source and refine
- · Bring TLR 5 to 9
Phase 2
ProtoCo
Feasibility Testing
- · Project team focused on Proof of Concept
- · IP and patent assessment
- · Team formation
- · Network engaged to stress-test
Phase 3
NewCo
Internal Build
- · Execute product and go-to-market plan
- · Assemble broader team and board
- · Sterinnova leadership as founding operator
Phase 4
ScaleCo
Spin-out / Exit
- · Governance and board of directors established
- · Separate from Sterinnova resources
- · Scale
Cambridge · Kendall Square
Built in the heart of the MIT innovation district.
Steps from MIT and the world's densest cluster of biotech, medtech, and deep-tech talent, exactly where infection risk control innovation should be born.
Studio Numbers
The studio model outperforms.
Historical averages across venture studios.
Studio IRR vs Traditional Fund
Time to Series A
Reach Series A
Idea to Seed Round
Studio-born companies outperform on every metric.
The Sterilization Value Chain
Get in Touch
Let's build what's next.
Whether you're a founder, researcher, or investor in infection risk control, we'd like to hear from you.
Location
Cambridge, MA · Kendall Square